+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.

Age: 16Years - 80YearsAll GendersPhase 3
499 locations
C

Actively Recruiting

Researchers are comparing the safety and effectiveness of laparoscopic cholecystectomy versus a wait-and-see approach in elderly patients who have had successful endoscopic removal of common bile duct stones. The study aims to determine if waiting without immediate surgery is not worse than having the gallbladder removed laparoscopically. The main goal is to observe death, major postoperative complications, or recurrent biliary disease within one year after randomization. Four hundred participants aged 75 or older with cleared bile duct stones are randomly assigned to one of two groups. One group receives laparoscopic cholecystectomy within two weeks after stone removal, while the other group is managed without surgery initially but can have cholecystectomy later if needed. An interim safety analysis is planned after 100 participants to ensure no significant differences arise between groups. The trial may end early if strong evidence shows a difference in outcomes. Participants are followed for up to one year after randomization to track the composite outcome of death, major complications, or biliary events. Researchers also monitor quality of life, survival, healthcare costs, and pain related to biliary issues at various time points. The study includes assessments at 30, 180, and 365 days, with additional monitoring of hospitalizations and complications extending to two years in some measures.

Age: 75Years +All GendersPhase Not Applicable
12 locations
C

Actively Recruiting

This research evaluates the use of drug-coated balloons DCB compared to drug-eluting stents DES in patients with stable coronary artery disease CAD or acute coronary syndrome ACS who are at high risk of bleeding. The study aims to test whether using DCB with a shorter dual antiplatelet therapy DAPT regimen is not worse than using DES with a longer DAPT duration. If the DCB strategy is found not inferior, its superiority over DES will be further assessed. Participants will receive either a DCB or a DES during percutaneous coronary intervention PCI. The DCB group uses the SeQuent Please device combined with a tailored antithrombotic regimen based on patient stability and oral anticoagulation use. The DES group involves implantation of various CE-marked drug-eluting stents alongside individualized antithrombotic treatment. Treatment regimens vary between stable patients and those with ACS, with differences in DAPT duration and lifelong therapies. Throughout the study, participants are monitored for major adverse cardiac events MACE and bleeding episodes using the BARC classification over 12 months as the primary outcome. Additional outcomes include mortality, revascularization events, myocardial infarction, stroke, and bleeding tracked up to 36 months. The study uses a randomized, triple-blind design to compare these treatments with ongoing safety and efficacy assessments.

Age: 18Years +All GendersPhase Not Applicable
14 locations
N

Actively Recruiting

Healthy Volunteer

Endometriosis is a long-lasting condition where tissue similar to the lining inside the uterus grows outside it, causing pain and fertility problems for many women of reproductive age. This research aims to find specific RNA and protein markers in endometriosis tissue and normal uterine lining to help develop new treatments and diagnostic tools. The study also seeks to identify markers that predict disease progression and infertility through a detailed 10-year follow-up. Participants include women aged 19 to 48 years either with surgically confirmed endometriosis or healthy women without endometriosis confirmed by laparoscopy during sterilization. The study involves collecting tissue samples during surgery by laparoscopy or laparotomy for analysis of hormone metabolism and gene expression. Healthy volunteers are also included to provide comparison samples. During the study, researchers will collect samples during surgery and follow participants annually for up to 10 years using questionnaires about pain symptoms, fertility, and treatments. The study measures hormone levels and gene expression in tissues and blood, and tracks pain recurrence after surgery. This long-term follow-up aims to better understand disease behavior and support development of personalized treatment options.

Age: 19Years - 48YearsFEMALE
4 locations
C

Actively Recruiting

The trial investigates two different ways to stop high flow nasal cannula treatment in infants with acute bronchiolitis, a common cause of hospitalization in young children. Researchers want to find out if stopping the therapy immediately is safe and helps to reduce hospital stay, compared to slowly reducing the flow rate. Acute bronchiolitis mainly affects infants under one year and currently has no effective medication treatment in Finland. Participants will receive one of two approaches either the high flow nasal cannula is stopped immediately or the flow rate is gradually decreased until it ends. Typical high flow rates used are about 2 liters per kilogram per minute. The study compares these two strategies to see which method is more effective and safe for infants. During the study, infants will be monitored for treatment success, hospital stay length, and any readmissions within a week after discharge. Oxygen levels and suitability for ending therapy will be assessed by doctors. Researchers will measure hospitalization time starting from when they are assigned to a treatment method. The trial lasts for one week after randomization, with safety and treatment failure closely observed.

Age: 0Months - 12MonthsAll GendersPhase Not Applicable
4 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to understand how the loop electrosurgical excision procedure LEEP affects sexual function and quality of life in women with HPV-related cervical lesions. The study compares women undergoing LEEP to those who only have colposcopy visits, focusing on any changes in sexual function and health-related quality of life over time. The research is conducted across multiple centers and includes women referred for colposcopy due to cytological abnormalities or repeated HPV positivity. Participants are divided into two groups one receiving the LEEP treatment, which removes the affected cervical area using a small electric loop under local anesthesia, and a control group undergoing only colposcopy without LEEP. The study follows women over several years, with assessments planned at the first visit, then at 6 months, 24 months, 3 years, and 5 years after the initial procedure or colposcopy. During the study, participants complete web-based questionnaires about their sexual function using the Female Sexual Function Index FSFI and health-related quality of life using the 15D questionnaire. Researchers also collect background information from patient files and questionnaires. No additional visits or sample collections are required. The main outcomes measured are self-reported sexual function and quality of life scores over the follow-up period, with data securely managed and stored for analysis.

Age: 18Years - 70YearsFEMALE
5 locations
P

Actively Recruiting

This research investigates the use of stereotactic body radiotherapy SBRT to reduce the risk of postoperative pancreatic fistula POPF in patients undergoing pancreatoduodenectomy who are at very high risk due to a soft pancreas and a small pancreatic duct diameter of 3 millimeters or less. The study compares SBRT before surgery versus conventional treatment to see if SBRT can induce pancreatic atrophy, which may decrease the chance of a serious pancreatic leak after surgery. The study involves multiple hospitals in Finland and focuses on patients with specific high-risk features for POPF. Participants are randomly assigned to one of two groups one group receives SBRT targeting the remnant pancreas with a total dose of 19.8 Gy delivered in three fractions 4 to 6 weeks before surgery, while the other group undergoes the standard pancreatoduodenectomy without preoperative radiotherapy. SBRT is a precise radiation method designed to cause fibrotic changes in the pancreas, potentially reducing its exocrine function and thus the risk of fistula development. The study evaluates the effects of SBRT on pancreatic tissue and function, surgical complications, and quality of life. Throughout the trial, participants are monitored for postoperative pancreatic fistula occurrence within 90 days after surgery, as well as other outcomes such as pancreatic fibrosis assessed by MRI and elastography, adverse events related to SBRT, surgical complications, mortality, hospital stay length, readmissions, pancreatic endocrine and exocrine function changes, and healthcare costs. Researchers also analyze radiological and tissue changes caused by SBRT. The total duration for each participant includes preoperative radiotherapy if assigned, surgery, and follow-up assessments extending at least three months after surgery.

Age: 18Years +All GendersPhase Not Applicable
3 locations
P

Actively Recruiting

Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.

Age: 65Years +All GendersPhase 3
789 locations